484 related articles for article (PubMed ID: 16494499)
1. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
[TBL] [Abstract][Full Text] [Related]
2. Modeling of Neuropeptide Receptors Y1, Y4, Y5, and Docking Studies with Neuropeptide Antagonist Analogues: Implications for Selectivity.
Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
J Biomol Struct Dyn; 2004 Aug; 22(1):497-508. PubMed ID: 22640480
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
Cabrele C; Beck-Sickinger AG
J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
[TBL] [Abstract][Full Text] [Related]
4. Cloning and characterization of rabbit neuropeptide Y receptor subtypes.
Umeda T; Kanatani A; Iwaasa H
Peptides; 2009 Aug; 30(8):1441-7. PubMed ID: 19481128
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
[TBL] [Abstract][Full Text] [Related]
6. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
[TBL] [Abstract][Full Text] [Related]
7. Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes.
Fällmar H; Åkerberg H; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Neuropeptides; 2011 Aug; 45(4):293-300. PubMed ID: 21696823
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
[TBL] [Abstract][Full Text] [Related]
10. Modulation of neuropeptide Y receptors for the treatment of obesity.
Sato N; Ogino Y; Mashiko S; Ando M
Expert Opin Ther Pat; 2009 Oct; 19(10):1401-15. PubMed ID: 19743896
[TBL] [Abstract][Full Text] [Related]
11. Molecular evolution of NPY receptor subtypes.
Larhammar D; Salaneck E
Neuropeptides; 2004 Aug; 38(4):141-51. PubMed ID: 15337367
[TBL] [Abstract][Full Text] [Related]
12. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation.
Sørensen G; Lindberg C; Wörtwein G; Bolwig TG; Woldbye DP
J Neurosci Res; 2004 Sep; 77(5):723-9. PubMed ID: 15352219
[TBL] [Abstract][Full Text] [Related]
13. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function.
Gehlert DR; Shaw JL
Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review).
Spinazzi R; Andreis PG; Nussdorfer GG
Int J Mol Med; 2005 Jan; 15(1):3-13. PubMed ID: 15583821
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors.
Beck-Sickinger AG; Jung G
Biopolymers; 1995; 37(2):123-42. PubMed ID: 7893945
[TBL] [Abstract][Full Text] [Related]
16. Properties of the N-terminal domains from Y receptors probed by NMR spectroscopy.
Zou C; Kumaran S; Walser R; Zerbe O
J Pept Sci; 2009 Mar; 15(3):184-91. PubMed ID: 19125388
[TBL] [Abstract][Full Text] [Related]
17. Studies of the structure of the N-terminal domain from the Y4 receptor - a G protein-coupled receptor - and its interaction with hormones from the NPY family.
Zou C; Kumaran S; Markovic S; Walser R; Zerbe O
Chembiochem; 2008 Sep; 9(14):2276-84. PubMed ID: 18767100
[TBL] [Abstract][Full Text] [Related]
18. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.
Criscione L; Rigollier P; Batzl-Hartmann C; Rüeger H; Stricker-Krongrad A; Wyss P; Brunner L; Whitebread S; Yamaguchi Y; Gerald C; Heurich RO; Walker MW; Chiesi M; Schilling W; Hofbauer KG; Levens N
J Clin Invest; 1998 Dec; 102(12):2136-45. PubMed ID: 9854049
[TBL] [Abstract][Full Text] [Related]
19. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
Kanatani A; Ishihara A; Iwaasa H; Nakamura K; Okamoto O; Hidaka M; Ito J; Fukuroda T; MacNeil DJ; Van der Ploeg LH; Ishii Y; Okabe T; Fukami T; Ihara M
Biochem Biophys Res Commun; 2000 May; 272(1):169-73. PubMed ID: 10872822
[TBL] [Abstract][Full Text] [Related]
20. Biophysical methods to study ligand-receptor interactions of neuropeptide Y.
Bettio A; Beck-Sickinger AG
Biopolymers; 2001; 60(6):420-37. PubMed ID: 12209475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
